and Experiences. Editio Cantor Verlag: Aulendorf,
Germany (ISBN 3-87193-284-1).
FDA Guidance for Industry: Guideline for the Monitor-
ing of Clinical Investigations, January 1988.
Accessed January 1, 2006, at http://www.fda.gov/
ora/compliance_ref/bimo/clinguid.html.
FDA Guidance for Industry: Guideline for the Prepara-
tion of Investigational New Drug Products (Human
andAnimal),March1991. Accessed January 1, 2006,
at http://www.fda.gov/cder/guidance/old042fn.pdf.
FDA Guidance for Industry: Computerized Systems
Used in Clinical Trials, April 1999. Accessed Jan-
uary 1, 2006, at http://www.fda.gov/ora/complian-
ce_ref/bimo/ffinalcct.pdf.
FDA 21 CFR Part 11.Electronic Records, Electronic
Signatures. Accessed January 1, 2006, at http://
http://www.fda.gov/oc/gcp/regulations.html.
FDA 21 CFR Part 50.Protection of Human Subjects.
Accessed January 1, 2006, at http://www.fda.gov/oc/
gcp/regulations.html.
FDA 21 CFR Part 54.Financial Disclosure by Clinical
Investigators. Accessed January 1, 2006, at http://
http://www.fda.gov/oc/gcp/regulations.html.
FDA 21 CFR Part 56.Institutional Review Boards.
Accessed January 1, 2006, at http://www.fda.gov/
oc/gcp/regulations.html.
FDA 21 CFR Part 312. Investigational New Drug
Application. Accessed January 1, 2006, at http://
http://www.fda.gov/oc/gcp/regulations.html.
FDA 21 CFR Part 314.Applications for FDA Approval
to Market a New Drug. Accessed January 1, 2006, at
http://www.fda.gov/oc/gcp/regulations.html.
FDACompliance Program Guidance Manual 7348.810 –
Sponsors, Contract Research Organizations and
Monitors, 21 February 2001. Accessed January 1,
2006, at http://www.fda.gov/ora/compliance_ref/
bimo/7348_810/48-810.pdf.
FDA Guidance for Industry, Investigators, and
Reviewers: Exploratory IND Studies, January
2006. Accessed February 1, 2006, at http://
http://www.fda.gov/cder/guidance/7086fnl.pdf.
FDA Guidance for Industry: Content and Format
of Investigational New Drug Applications (INDs)
for Phase I Studies of Drugs, Including Well-
Characterized, Therapeutic, Biotechnology-derived
Products, November 1995. Accessed January 1,
2006, at http://www.fda.gov/cder/guidance/phase1.pdf.
Follett T. 2003.Computer Validation: The 100 Worst
Mistakes You Can Make. CVSI Press; Richville, NY,
USA (ISBN 0-9705456-1-4).
Hattemer-Apostel R. 2000a. GCP auditors: hard to find –
hard to develop – hard to keep: part 1. Criteria and
methods for candidate selection.Qual. Assur. J. 4 (1):
3–8.
Hattemer-Apostel R. 2000b. GCP auditors: hard to find –
hard to develop – hart to keep: part 2. Initial training
requirements for auditors.Qual. Assur. J. 4 (3): 123–
135.
Hattemer-Apostel R. 2001. GCP auditors: hard to find –
hard to develop – hard to keep: part 3. Continuous
educationandfurtherdevelopment.Qual.Assur.J. 5 (1):
3–11.
Hattemer-Apostel R. 2003. A career in clinical quality
assurance. In Careers With the Pharmaceutical
Industry, Stonier PD (ed.). 2nd edition. John Wiley
& Sons Ltd.: Chichester, England; 188–202 (ISBN
0-470-84328-4).
Hattemer-Apostel R. 2004. Quality assurance and clin-
ical research. InClinical Research Manual, Lus-
combe D, Stonier PD (eds.). Euromed
Communications Ltd.; Haslemere: 17.1–17.46
(ISSN 1355-4808).
ICH Note for Guidance on Structure and Content of
Clinical Study Reports (CPMP/ICH/137/95). 1995.
Accessed January 1, 2006, at http://www.ich.org.
ICH Note for Guidance on Good Clinical Practice
(CPMP/ICH/135/95). 1995. Accessed January 1,
2006, at http://www.ich.org.
ICH Note for Guidance on Statistical Principles for
Clinical Trials (CPMP/ICH/363/96). 1998. Accessed
January 1, 2006, at http://www.ich.org.
ISO 19011:2002.Guidelines for Quality and/or Envir-
onmental Management Systems Auditing, 3 October
2002. Available at http://www.iso.org.
ISO 9000:2005.Quality Management Systems–Fun-
damentals and Vocabulary, 20 September 2005.
Available at http://www.iso.org.
Isidor JM, Kaltmann SP. 1999. Clueless? Which state
laws do you need to know before conducting
research at your site? Accessed January 1, 2006,
at http://www.sairb.com/articles/4.html.
Lock S, Wells F, Farthing M (eds.). 2001.Fraud and
Misconduct in Biomedical Research. 3rd edition.
BMJ Publishing Group: London, England (ISBN
0-7279-1508-8).
McDowall RD. 2005. Effective and practical risk man-
agement options for computerised systems valida-
tion.Qual. Assur. J. 9 (3): 196–227.
PIC/S Guidance Good Practices for Computerized
Systems in Regulated ‘GXP’ Environments (PI
011-2), 1 July 2004. Accessed January 1, 2006, at
http://www.picscheme.org.
PIC/S Aide-Me ́moire GMP Particularities in the
Manufacture of Medicinal Products to be Used inREFERENCES 177